Nanomedicine, particularly liposomal drug delivery, has expanded considerably over the
past few decades, and several liposomal drugs are already providing improved clinical …

The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context …

Liposomes have gained increased attention as systemic drug delivery vehicles following
recent regulatory approvals of several vesicle-formulated drugs. These products have …

The use of liposomes for drug delivery began early in the history of pharmaceutical
nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug …

Liposomes have been exploited for pharmaceutical purposes, including diagnostic imaging
and drug and gene delivery. The versatility of liposomes as drug carriers has been …

Liposomes, the most widely studied nano-drug carriers in drug delivery, are sphere-shaped
vesicles consisting of one or more phospholipid bilayers. Compared with traditional drug …

Liposomes have gained increased attention as systemic drug delivery vehicles following
recent regulatory approvals of several vesicle-formulated drugs. These products have …

The liposome, a closed phospholipid bilayered vesicular system, has received considerable
attention as a pharmaceutical carrier of great potential over the past 30 years. The ability of …

Cancer remains a deadly disease for effective treatment. Although anomalous tumor
microenvironment is now widely exploited for targeted chemotherapy, safe and efficacious …

Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed
selectively or over-expressed on tumor cells is increasingly being recognized as an effective …